Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H22I3N3O8 |
Molecular Weight | 777.0853 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I
InChI
InChIKey=XQZXYNRDCRIARQ-LURJTMIESA-N
InChI=1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1
DescriptionCurator's Comment: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae8c18c9-3e7d-4515-b980-120025a88fc1
http://www.rxlist.com/isovue-drug.htm
Curator's Comment: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae8c18c9-3e7d-4515-b980-120025a88fc1
http://www.rxlist.com/isovue-drug.htm
Iopamidol is a nonionic, low-osmolar iodinated contrast agent. Iopamidol is indicated for angiography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography, and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic. Renal toxicity has been reported in a few patients with liver dysfunction who were given oral cholecystographic agents followed by intravascular contrast agents. Intravascular injection of contrast media is frequently associated with the sensation of warmth and pain especially in peripheral arteriography and venography. In angiocardiography the adverse reactions are: hot flashes, angina pectoris, flushing, bradycardia, hypotension, hives.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: vessels and anatomical structures |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | ISOVUE-M 300 Approved UseISOVUE-M (lopamidol Injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. ISOVUE-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years. Launch Date5.04835211E11 |
|||
Diagnostic | ISOVUE-M 300 Approved UseISOVUE-M (lopamidol Injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. ISOVUE-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years. Launch Date5.04835211E11 |
|||
Diagnostic | ISOVUE-M 300 Approved UseISOVUE-M (lopamidol Injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. ISOVUE-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years. Launch Date5.04835211E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
112.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3096110 |
15 mL single, intrathecal dose: 15 mL route of administration: Intrathecal experiment type: SINGLE co-administered: |
IOPAMIDOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
931 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3096110 |
15 mL single, intrathecal dose: 15 mL route of administration: Intrathecal experiment type: SINGLE co-administered: |
IOPAMIDOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2 h |
single, intravenous |
IOPAMIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9084958 |
IOPAMIDOL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
61 % single, intravenous Dose: 61 % Route: intravenous Route: single Dose: 61 % Sources: |
unhealthy, 21 years n = 1 Health Status: unhealthy Condition: disseminated lupus erythematosus manifested mainly by lupus nephritis, computed tomography Age Group: 21 years Sex: F Population Size: 1 Sources: |
Disc. AE: Hepatotoxicity... AEs leading to discontinuation/dose reduction: Hepatotoxicity (1 patient) Sources: |
612 mg/mL single, intrathecal Dose: 612 mg/mL Route: intrathecal Route: single Dose: 612 mg/mL Sources: |
unknown, 45 years n = 1 Health Status: unknown Condition: cervical myelography Age Group: 45 years Sex: M Population Size: 1 Sources: |
Disc. AE: Generalized tonic-clonic seizure... AEs leading to discontinuation/dose reduction: Generalized tonic-clonic seizure (1 patient) Sources: |
54250 mg single, intravenous Dose: 54250 mg Route: intravenous Route: single Dose: 54250 mg Sources: |
unknown, adult and children n = 2074 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 2074 Sources: |
Other AEs: Extravasation... |
62775 mg single, intravenous Dose: 62775 mg Route: intravenous Route: single Dose: 62775 mg Sources: |
unknown, adult and children n = 1851 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 1851 Sources: |
Other AEs: Extravasation... |
68544 mg single, intravenous Dose: 68544 mg Route: intravenous Route: single Dose: 68544 mg Sources: |
unknown, adult and children n = 10064 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10064 Sources: |
Other AEs: Extravasation... |
69768 mg single, intravenous Dose: 69768 mg Route: intravenous Route: single Dose: 69768 mg Sources: |
unknown, adult and children n = 10831 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10831 Sources: |
Other AEs: Extravasation... |
83700 mg single, intravenous Dose: 83700 mg Route: intravenous Route: single Dose: 83700 mg Sources: |
unknown, adult and children n = 1851 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 1851 Sources: |
Other AEs: Allergic reaction... |
87516 mg single, intravenous Dose: 87516 mg Route: intravenous Route: single Dose: 87516 mg Sources: |
unknown, adult and children n = 10064 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10064 Sources: |
Other AEs: Allergic reaction... |
88740 mg single, intravenous Dose: 88740 mg Route: intravenous Route: single Dose: 88740 mg Sources: |
unknown, adult and children n = 10831 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10831 Sources: |
Other AEs: Allergic reaction... |
612 mg/mL single, intravenous Dose: 612 mg/mL Route: intravenous Route: single Dose: 612 mg/mL Sources: |
unknown, adult and children n = 10064 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10064 Sources: |
Other AEs: Adverse event... |
612 mg/mL single, intravenous Dose: 612 mg/mL Route: intravenous Route: single Dose: 612 mg/mL Sources: |
unknown, adult and children n = 10831 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10831 Sources: |
Other AEs: Adverse event... |
61225 mg/mL single, intravenous Dose: 61225 mg/mL Route: intravenous Route: single Dose: 61225 mg/mL Sources: |
unknown, adult and children n = 2074 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 2074 Sources: |
Other AEs: Allergic reaction... |
775 mg/mL single, intravenous Dose: 775 mg/mL Route: intravenous Route: single Dose: 775 mg/mL Sources: |
unknown, adult and children n = 1851 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 1851 Sources: |
Other AEs: Adverse event... |
775 mg/mL single, intravenous Dose: 775 mg/mL Route: intravenous Route: single Dose: 775 mg/mL Sources: |
unknown, adult and children n = 2074 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 2074 Sources: |
Other AEs: Adverse event... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hepatotoxicity | 1 patient Disc. AE |
61 % single, intravenous Dose: 61 % Route: intravenous Route: single Dose: 61 % Sources: |
unhealthy, 21 years n = 1 Health Status: unhealthy Condition: disseminated lupus erythematosus manifested mainly by lupus nephritis, computed tomography Age Group: 21 years Sex: F Population Size: 1 Sources: |
Generalized tonic-clonic seizure | 1 patient Disc. AE |
612 mg/mL single, intrathecal Dose: 612 mg/mL Route: intrathecal Route: single Dose: 612 mg/mL Sources: |
unknown, 45 years n = 1 Health Status: unknown Condition: cervical myelography Age Group: 45 years Sex: M Population Size: 1 Sources: |
Extravasation | 18 patients | 54250 mg single, intravenous Dose: 54250 mg Route: intravenous Route: single Dose: 54250 mg Sources: |
unknown, adult and children n = 2074 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 2074 Sources: |
Extravasation | 5 patients | 62775 mg single, intravenous Dose: 62775 mg Route: intravenous Route: single Dose: 62775 mg Sources: |
unknown, adult and children n = 1851 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 1851 Sources: |
Extravasation | 23 patients | 68544 mg single, intravenous Dose: 68544 mg Route: intravenous Route: single Dose: 68544 mg Sources: |
unknown, adult and children n = 10064 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10064 Sources: |
Extravasation | 32 patients | 69768 mg single, intravenous Dose: 69768 mg Route: intravenous Route: single Dose: 69768 mg Sources: |
unknown, adult and children n = 10831 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10831 Sources: |
Allergic reaction | 3 patients | 83700 mg single, intravenous Dose: 83700 mg Route: intravenous Route: single Dose: 83700 mg Sources: |
unknown, adult and children n = 1851 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 1851 Sources: |
Allergic reaction | 46 patients | 87516 mg single, intravenous Dose: 87516 mg Route: intravenous Route: single Dose: 87516 mg Sources: |
unknown, adult and children n = 10064 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10064 Sources: |
Allergic reaction | 42 patients | 88740 mg single, intravenous Dose: 88740 mg Route: intravenous Route: single Dose: 88740 mg Sources: |
unknown, adult and children n = 10831 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10831 Sources: |
Adverse event | 69 patients | 612 mg/mL single, intravenous Dose: 612 mg/mL Route: intravenous Route: single Dose: 612 mg/mL Sources: |
unknown, adult and children n = 10064 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10064 Sources: |
Adverse event | 74 patients | 612 mg/mL single, intravenous Dose: 612 mg/mL Route: intravenous Route: single Dose: 612 mg/mL Sources: |
unknown, adult and children n = 10831 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 10831 Sources: |
Allergic reaction | 8 patients | 61225 mg/mL single, intravenous Dose: 61225 mg/mL Route: intravenous Route: single Dose: 61225 mg/mL Sources: |
unknown, adult and children n = 2074 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 2074 Sources: |
Adverse event | 8 patients | 775 mg/mL single, intravenous Dose: 775 mg/mL Route: intravenous Route: single Dose: 775 mg/mL Sources: |
unknown, adult and children n = 1851 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 1851 Sources: |
Adverse event | 26 patients | 775 mg/mL single, intravenous Dose: 775 mg/mL Route: intravenous Route: single Dose: 775 mg/mL Sources: |
unknown, adult and children n = 2074 Health Status: unknown Condition: computed tomography Age Group: adult and children Sex: unknown Population Size: 2074 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Iotrolan versus iopamidol. A controlled double-blind study with lumbar myelography]. | 1992 Aug |
|
Thrombogenic potential of contrast media in an experimental model of laser-induced thrombosis. | 2000 Nov 1 |
|
Iodinated radiographic contrast media inhibit the capacitative calcium entry into smooth muscle cells of the swine renal artery. | 2001 Dec |
|
Selective nerve root blocks for the treatment of sciatica: evaluation of injection site and effectiveness--a study with patients and cadavers. | 2001 Dec |
|
Safety and accuracy of bedside carbon dioxide cavography for insertion of inferior vena cava filters in the intensive care unit. | 2001 Feb |
|
Assessment of radiocontrast media induced renal vasoconstriction by color coded duplex sonography. | 2001 Jan |
|
[Severe thrombocytopenia induced by radiographic non-ionic contrast medium]. | 2001 Jun |
|
Vaginitis emphysematosa: CT and review of the literature. | 2001 Mar |
|
Diagnostic accuracy of computed tomography for cervical metastases at different anatomical levels in carcinoma of the tongue. | 2001 Sep |
|
Pericaval fat collection mimicking an intracaval lesion on CT in patients with chronic liver disease. | 2001 Sep-Oct |
|
Effect of iomeprol on rat hippocampal slice synaptic transmission: comparison with other X-ray contrast agents. | 2002 Apr |
|
Usefulness of multislice computed tomography for detecting obstructive coronary artery disease. | 2002 Apr 15 |
|
[Method of injection of contrast medium for brain perfusion CT]. | 2002 Jul |
|
Administration of nonionic iodinated contrast medium does not influence the outcome of patients with ischemic brain infarction. | 2003 |
|
Roles of intracellular Ca2+ and cyclic AMP in mast cell histamine release induced by radiographic contrast media. | 2003 Apr |
|
Nephrotoxicity of iopamidol in pediatric, adolescent, and young adult patients who have undergone allogeneic bone marrow transplantation. | 2003 Feb |
|
Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. | 2003 Feb 5 |
|
Delayed side effects induced by iodinated contrast media, especially those associated with iodixanol. | 2003 Mar |
|
Early and late reactions following the use of iopamidol 340, iomeprol 350 and iodixanol 320 in cardiac catheterization. | 2003 Mar |
|
Sonographic versus magnetic resonance arthrographic evaluation of full-thickness rotator cuff tears in millimeters. | 2003 Mar-Apr |
|
CT arthrography of the glenohumeral joint: CT fluoroscopy versus conventional CT and fluoroscopy--comparison of image-guidance techniques. | 2003 Oct |
|
Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study. | 2003 Oct |
|
Fate of pharmaceuticals--photodegradation by simulated solar UV-light. | 2003 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Dosage and administration depends on analysis type, patient age and contrast agent concentration. ISOVUE is available in different concentrations: 128, 200, 250, 300 and 370 mgI/ml.
Peripheral Arteriograghy: For injection into the femoral artery or subclavian artery, 5 to 40 mL of ISOVUE-300 may be used; for injection into the aorta for a distal runoff, 25 to 50 mL may be used. Doses up to a total of 250 mL of ISOVUE-300 have been administered during peripheral arteriography.
Route of Administration:
Intravascular
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1630618
Curator's Comment: Iopamidol increases the clotting time.
http://www.ncbi.nlm.nih.gov/pubmed/2745021
Diffusion of iopamidol (300 and 200 mgI/ml) was studied in the cerebrospinal fluid (CSF). Test tubes containing CSF were kept in a waterbath at 37 degrees C. Contrast medium was injected along the wall into the tubes, and diffusion of contrast media in the tubes was followed with repeated computed tomography for 5 h. The contents of the tubes were then mixed by shaking, and the tubes were scanned immediately and 8 h later.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28500
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
||
|
WHO-VATC |
QV08AB04
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
||
|
WHO-ATC |
V08AB04
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
||
|
NDF-RT |
N0000010258
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
||
|
NDF-RT |
N0000180185
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1464
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
IOPAMIDOL
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
CHEMBL1200932
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
JR13W81H44
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
31711
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
100000091432
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
60166-93-0
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
D007479
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
262-093-6
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
1344702
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
SUB08239MIG
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
m6370
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | Merck Index | ||
|
65492
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
8075
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
C47567
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
Iopamidol
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
DB08947
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
JR13W81H44
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
DTXSID1023158
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
4399
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | |||
|
5966
Created by
admin on Fri Dec 15 15:00:05 UTC 2023 , Edited by admin on Fri Dec 15 15:00:05 UTC 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY